0.899

1.32% +0.0117

After Hours: .8803 -0.0187 -2.08%

Hookipa Pharma Inc (HOOK)

Overview News Price History Option Chain Discussions Forecast

Hookipa Pharma Inc stock is currently priced at $0.899, with a 24-hour trading volume of 414.41K. It has seen a +1.32% increased in the last 24 hours and a +24.26% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.9124 pivot point. If it approaches the $0.8549 support level, significant changes may occur.

Previous Close:

$0.8873

Open:

$0.8757

24h Volume:

414.41K

Market Cap:

$88.96M

Revenue:

$20.55M

Net Income/Loss:

$-69.07M

P/E Ratio:

-0.9879

EPS:

-0.91

Net Cash Flow:

$-37.50M

1W Performance:

+5.76%

1M Performance:

+24.26%

6M Performance:

+113.54%

1Y Performance:

-17.52%

1D Range:

$0.851

$0.92

52W Range:

$0.41

$2.05

Hookipa Pharma Inc Stock (HOOK) Company Profile

Name

Hookipa Pharma Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

431 890 6360

Address

350 Fifth Avenue, 72nd Floor Suite 7240, New York, NY

Employee

131

Twitter

@HookipaPharma

Next Earnings Date

2024-05-09

Latest SEC Filings

HOOK's Discussions on Twitter

Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-22	Downgrade	BofA Securities	Buy → Underperform
Nov-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-08-21	Initiated	Morgan Stanley	Overweight
Nov-03-20	Initiated	Truist	Buy
Oct-26-20	Initiated	JMP Securities	Mkt Outperform
Oct-19-20	Resumed	H.C. Wainwright	Buy
Sep-27-19	Initiated	H.C. Wainwright	Buy
May-13-19	Initiated	BofA/Merrill	Buy
May-13-19	Initiated	RBC Capital Mkts	Outperform

View All

Hookipa Pharma Inc Stock (HOOK) Latest News

Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views

Benzinga

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

GlobeNewswire Inc.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

GlobeNewswire Inc.

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

GlobeNewswire Inc.

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Hookipa Pharma Inc Stock (HOOK) Financials Data

Hookipa Pharma Inc (HOOK) Revenue 2024

HOOK reported a revenue (TTM) of $20.55 million for the quarter ending September 30, 2023, a +99.21% rise year-over-year.

Hookipa Pharma Inc (HOOK) Net Income 2024

HOOK net income (TTM) was -$69.07 million for the quarter ending September 30, 2023, a +6.45% increase year-over-year.

Hookipa Pharma Inc (HOOK) Cash Flow 2024

HOOK recorded a free cash flow (TTM) of -$37.50 million for the quarter ending September 30, 2023, a +32.96% increase year-over-year.

Hookipa Pharma Inc (HOOK) Earnings per Share 2024

HOOK earnings per share (TTM) was -$0.83 for the quarter ending September 30, 2023, a +45.75% growth year-over-year.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.